Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 47Gynecologic 20CNS 10Lymphoid 5Breast 5Gastrointestinal 4Other neoplasm 3Genitourinary 3Other hematologic neoplasm 2Head & Neck 2Tumor-Agnostic 1Thoracic 1Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cytarabine 898Cyclophosphamide 892fludarabine 516venetoclax 473fludarabine phosphate 464Azacitidine 450Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 227Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 202Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 160Mitoxantrone 160Lenalidomide 159Antilymphocyte Serum 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Imiquimod × Other hematologic neoplasm × Clear all
NCT03559413 2023-12-04

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

University Children's Hospital Tuebingen

Phase 1/2 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02802943 2022-11-28

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

University Hospital Tuebingen

Phase 2 Completed
56 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡